Ravi Salgia to Immunotherapy
This is a "connection" page, showing publications Ravi Salgia has written about Immunotherapy.
Connection Strength
0.656
-
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018 01 23; 6(1):8.
Score: 0.432
-
Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma. Cold Spring Harb Mol Case Stud. 2023 04; 9(2).
Score: 0.156
-
Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. Semin Cancer Biol. 2022 08; 83:57-76.
Score: 0.033
-
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63.
Score: 0.022
-
Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res. 2008 Jun 15; 14(12):3896-905.
Score: 0.014